The edition · Oncology
Weekly symptom reporting in lung cancer was linked to five months' longer median survival
SYMPRO-Lung's five-year follow-up adds a survival signal to routine PRO monitoring. Also: an HCC guideline written for resource-limited settings, camrelizumab across the whole LS-SCLC pathway, and nudges that raised hereditary cancer testing.
The edition in brief
Today's oncology edition closes on patient-reported symptom monitoring. In a post hoc analysis of the Dutch SYMPRO-Lung stepped-wedge trial, 446 patients with stage I–IV lung cancer who completed weekly online symptom reports for a year had a median overall survival of 26 months against 21 months in the control period (adjusted HR 0.80, 0.63 to 1.00); progression-free survival did not differ. The IHPBA has issued a resource-sensitive guideline for hepatocellular carcinoma: ultrasound with cross-sectional confirmation, no mandatory biopsy, resection for limited disease with preserved liver function, thermal ablation or ethanol injection where resection is unavailable, and atezolizumab-bevacizumab first line with sorafenib or lenvatinib as alternatives. A 41-patient Chinese phase 2 trial in limited-stage small cell lung cancer reported 1-year PFS of 65.5% against 47.4% when camrelizumab was added to induction and consolidation, against a control arm without immunotherapy. In the MiGHT trial of 793 adults eligible for germline testing, digital and telephone coaching interventions raised testing, but only 9.6% overall were tested within a year. The pearl covers HCC surveillance.
IHPBA's HCC guideline is written for hospitals without every resource
Where resources are limited, match HCC treatment to the best available option at each stage rather than defaulting to supportive care.
Camrelizumab across induction and consolidation in limited-stage SCLC: an early signal
Treat camrelizumab added at induction in limited-stage SCLC as an early signal, not a reason to change the current standard.
Digital and coaching nudges raised hereditary cancer testing, from a low base
Offer germline testing at the point eligibility is recognised and confirm it was completed; education alone leaves most untested.
Six-monthly ultrasound in cirrhosis, if the patient could be treated
Put every patient with cirrhosis who would be fit for treatment on six-monthly ultrasound surveillance with a recall system.
Weekly online symptom reporting linked to longer survival in lung cancer
Consider adding weekly patient-reported symptom monitoring, with a clear response pathway, for patients on lung cancer treatment.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free